美国发布《2020-2030年国家流感疫苗现代化战略》.pdfVIP

National Influenza Vaccine Modernization Strategy 2020-2030 CONTENTS Executive Summary 2 Introduction 3 Vision and Strategic Objectives 4 Guiding Principles 5 Strategic Objectives 5 Strategic Objective 1: Strengthen and Diversify Influenza Vaccine Development, Manufacturing, and Supply Chain 5 Strategic Objective 2: Promote Innovative Approaches and Use of New Technologies to Detect, Prevent, and Respond to Influenza 6 Strategic Objective 3: Increase Influenza Vaccine Access and Coverage Across All Populations 7 Implementation Approach 8 Conclusion 9 Annex A: NIVMS Objectives Crosswalk to EO13887 10 NIVMS 2020-2030 1 EXECUTIVE SUMMARY Influenza poses a serious threat to national security and public health. Each year, seasonal influenza results in hundreds of thousands of hospitalizations and tens of thousands of deaths in the United States. Furthermore, influenza viruses have the potential to cause pandemics, which occur when a novel influenza virus – to which humans have little to no immunity – emerges, allowing the virus to spread easily from person-to-person. An influenza pandemic can occur at any time with little warning; any delay in detecting a novel influenza strain; sharing of influenza virus samples; and in developing, producing, distributing, or administering a therapeutic or vaccine could result in significant additional morbidity and mortality. Vaccination is currently the most effective strategy for preventing influenza infection. While substantial progress has been made in national influenza preparedness and prevention, significant gaps remain: domestic influenza vaccine production is inefficient and insufficient, vaccine effectiveness is less than optimal, and vaccination rates acro